Try our beta test site

Comparison of a Serum PRO-CT Guided Treatment and the Recommended Antibiotic Treatment for COPD

This study has been completed.
Sponsor:
Collaborator:
Agenzia Italiana del Farmaco
Information provided by (Responsible Party):
Leonardo M. Fabbri, University of Modena and Reggio Emilia
ClinicalTrials.gov Identifier:
NCT01125098
First received: April 13, 2010
Last updated: December 9, 2014
Last verified: December 2014
Results First Received: December 9, 2014  
Study Type: Observational
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Other: PRO-CT values

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The recruitment process involved18 university/city hospital pulmonary departments. Patients selected were subjects hospitalized because of severe exacerbation of COPD (increased dyspnea, sputum volume, and sputum purulence according to Anthonisen criteria and/or respiratory failure) requiring antibiotic treatment.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
PRO-CT Group: Experimental

COPD patients in the PRO-CT group will continue or discontinue antibiotic therapy depending on PRO-CT values.

PRO-CT values: - continue antibiotics for 10 days if a single PRO-CT value is 0.25 mcg/L or greater, that will be judged suggestive of bacterial infection

  • continue antibiotics from day 3 to day 10 if one or more PRO-CT values are 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, PLUS acute respiratory failure or clinical instability
  • stop antibiotics on day 3, if one or more PRO-CT values are between 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, BUT the patient has not acute respiratory failure or clinical instability
  • stop antibiotics if all the PRO-CT values are < 0.1 mcg/L or if there is a consistent trend to normalization of PRO-CT with the last value < 0.1 mcg/L, that will be judged suggestive of absence of bacterial infection.
Standard Group: No Intervention COPD patients in the Standard group will continue antibiotic therapy for 10 days according to guidelines recommended treatment plan in case of COPD exacerbations.

Participant Flow:   Overall Study
    PRO-CT Group: Experimental   Standard Group: No Intervention
STARTED   91   90 
COMPLETED   88   90 
NOT COMPLETED   3   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
PRO-CT Group: Experimental

COPD patients in the PRO-CT group will continue or discontinue antibiotic therapy depending on PRO-CT values.

PRO-CT values: - continue antibiotics for 10 days if a single PRO-CT value is 0.25 mcg/L or greater, that will be judged suggestive of bacterial infection

  • continue antibiotics from day 3 to day 10 if one or more PRO-CT values are 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, PLUS acute respiratory failure or clinical instability
  • stop antibiotics on day 3, if one or more PRO-CT values are between 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, BUT the patient has not acute respiratory failure or clinical instability
  • stop antibiotics if all the PRO-CT values are < 0.1 mcg/L or if there is a consistent trend to normalization of PRO-CT with the last value < 0.1 mcg/L, that will be judged suggestive of absence of bacterial infection.
Standard Group: No Intervention COPD patients in the Standard group will continue antibiotic therapy for 10 days according to guidelines recommended treatment plan in case of COPD exacerbations.
Total Total of all reporting groups

Baseline Measures
   PRO-CT Group: Experimental   Standard Group: No Intervention   Total 
Overall Participants Analyzed 
[Units: Participants]
 91   90   181 
Age [1] 
[Units: Years]
Median (Inter-Quartile Range)
 73.5 
 (68.5 to 78) 
 72.5 
 (65 to 78) 
 73 
 (66.5 to 78) 
[1] Age, median (IQR)
Gender 
[Units: Participants]
     
Female   11   13   24 
Male   80   77   157 
Region of Enrollment 
[Units: Participants]
     
Italy   91   90   181 


  Outcome Measures

1.  Primary:   To Evaluate the Rate of Severe Exacerbations in COPD, Comparing COPD Patients Previously Treated According to the PRO-CT Protocol Versus COPD Patients Previously Treated With Standard Antibiotic Therapy.   [ Time Frame: 6 months ]

2.  Secondary:   Cost/Effectiveness of the Use of PRO-CT-guided Decision Making Protocol on Duration of Antibiotic Therapy in COPD Exacerbations.   [ Time Frame: Discharge /10 days-6 months ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

3.  Secondary:   To Evaluate if the PRO-CT-guided Decision Making to Shorten Antibiotic Therapy is Less Effective Than the Guideline Recommended Standard Antibiotic Treatment in Preventing Hospitalization.   [ Time Frame: Discharge/10 days-6 months ]
Results not yet reported.   Anticipated Reporting Date:   11/2014  

4.  Secondary:   To Verify Survival in COPD Patients Comparing to Those Treated According to the PRO-CT Protocol Versus COPD Patients Treated With Standard Antibiotic Therapy.   [ Time Frame: Discharge/10 days-6 months ]
Results not yet reported.   Anticipated Reporting Date:   11/2014  

5.  Secondary:   To Verify Changes in FEV1 Value in COPD Patients Comparing Those Treated According to the PRO-CT Protocol Versus COPD Patients Treated With Standard Antibiotic Therapy.   [ Time Frame: Discharge/10 days-6 months ]
Results not yet reported.   Anticipated Reporting Date:   11/2014  

6.  Secondary:   To Verify the Duration of Hospitalization for Severe Exacerbation in COPD Patients Treated According to the PRO-CT Protocol Versus COPD Patients Treated With Standard Antibiotic Therapy.   [ Time Frame: Discharge/10 days-6 months ]
Results not yet reported.   Anticipated Reporting Date:   11/2014  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Leonardo Fabbri
Organization: Department of Oncology Haematology and Respiratory Diseases
phone: +39 059422 ext 4227
e-mail: leonardo.fabbri@unimore.it


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Leonardo M. Fabbri, University of Modena and Reggio Emilia
ClinicalTrials.gov Identifier: NCT01125098     History of Changes
Other Study ID Numbers: FARM58J2XH
Study First Received: April 13, 2010
Results First Received: December 9, 2014
Last Updated: December 9, 2014